GlassScriptPhysician profile
Lenore A Nigrelli
NPI 1275564569
$4,608.77
in general payments reported to CMS, 2019-2025
24 companies · $947 in 2025
The $947 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,324 · 2022: $859 · 2023: $583 · 2024: $895 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,425.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $695.30 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $571.83 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $569.62 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $496.19 | 2021-2024 | Xarelto |
| Amgen INC. | $463.08 | 2021-2025 | Repatha |
| Pfizer INC. | $375.30 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $251.16 | 2021-2025 | Verquvo |
| Edwards Lifesciences Corporation | $179.34 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| E.R. Squibb & Sons, L.L.C. | $136.58 | 2022-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $114.51 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.88 | 2021-2025 | |
| Novo Nordisk INC | $98.99 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Genzyme Corporation | $89.55 | 2024-2025 | |
| Boston Scientific Corporation | $85.60 | 2025 | Lux-Dx Insertable Cardiac Monitor |
| Astrazeneca Pharmaceuticals LP | $83.27 | 2022-2025 | Farxiga |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $72.46 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $46.03 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $36.00 | 2023 | Uptravi, Opsumit |
| Amarin Pharma, INC. | $31.20 | 2021 | |
| Abiomed | $30.92 | 2024 | Impella |
| Vifor Pharma, INC. | $23.35 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $18.49 | 2025 | Evkeeza |
| Amryt Pharma Holdings LTD | $16.56 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lenore Nigrelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.